Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women's diagnostic health products. Together with the Company's recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys' European expansion strategy and broadens access to its innovative technologies through experienced regional partners.